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Background: Several aggregate published reviews have compared the effectiveness of one- and two-stage surgical
revision to prevent re-infection following prosthetic hip infection and have reported inconsistent results. In addition,
there were several features of these previous reviews which limited the validity of the findings. In the absence of a
well-designed clinical trial, we propose the Global Infection Orthopaedic Management (INFORM) collaboration, a
worldwide collaborative systematic review and meta-analysis of individual participant data (IPD) to address the existing
uncertainties.
Methods: Cohort studies (prospective or retrospective) and randomised controlled trials conducted in unselected
patients with infection treated exclusively by one- or two-stage revision and reporting re-infection outcomes within 2
years of revision will be retrieved by searching the following databases: MEDLINE, EMBASE, Web of Science, Cochrane
Database of Systematic Reviews, Cochrane Central Register of Controlled Trials and the WHO International Clinical Trials
Registry Platform. Reference lists of relevant studies will be manually scanned and there will be email contact with
investigators of grey literature and conference abstracts. Investigators will be invited to join the Global INFORM
collaboration and share their individual level data. The primary outcome of the analyses will be incidence of re-infection
within 2 years of commencement of revision surgery. Primary analyses will be conducted comparing the one-stage to
the two-stage surgical revision. IPD analyses will be based on Cox proportional hazard (PH) models estimated for each
study separately. Study-specific log hazard ratios will be combined using random-effects meta-analysis with fixed-effects
meta-analysis in subsidiary analyses. Hazard ratios for re-infection according to different individual level characteristics
such as sex, age groups, body mass index and comorbidities will also be assessed.
Discussion: The analyses will enable a consistent approach to the definition of re-infection outcomes, more detailed
analyses under a broader range of circumstances and exploration of potential sources of heterogeneity and produce
much more valid and precise estimates of re-infection outcomes.
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Hip replacement is widely used to treat pain associated
with diseased or damaged joints. Deep prosthetic infec-
tion is an uncommon but serious complication of hip
replacement with estimated incidence in the UK popula-
tion of about 0.70% [1]. Prosthetic joint infection oc-
curring within 2 years of hip replacement is mainly a
consequence of the surgical intervention [2] and are com-
monly associated with extreme pain, restricted movement,
feelings of isolation, insecurity and hopelessness and may
even lead to death [3,4]. Treatment options for prosthetic
hip infection include the following: surgical removal of
dead, damaged and infected tissue (debridement) with
prosthesis retention and long-term antibiotic treatment;
debridement and the exchange of modular components;
one-stage revision; two-stage revision; excision of the joint
replacement; or amputation. One-stage surgical revision
involves prosthesis removal, debridement, antibiotic treat-
ment and joint replacement in the same surgical oper-
ation. In the two-stage revision, a temporary ‘spacer’ may
be fitted, which is replaced in the second operation typic-
ally 2 to 6 months later. The two-stage revision is used
commonly and has been traditionally regarded as more ef-
fective in treating infection [5,6]. In England and Wales,
about 500 hip revision procedures per year following pros-
thetic joint infection are carried out, with 30% being one-
stage revision, 64% being two-stage and 6% being excision
[7]. Despite the opportunities for additional microbial
strategies [8] with the two-stage procedure, patients who
undergo this procedure require additional hospital admis-
sions, undergo further major surgery and experience con-
siderable pain and disability during the period between
operations and sometimes after the revision [9]. A two-
stage revision may also cost about 70% more than a one-
stage revision [10]. There is an increasing interest in the
use of the single-stage revision as it may be associated
with significantly less morbidity and disability; may elimin-
ate the requirement for prolonged stay in the hospital; and
overall healthcare costs of this procedure may be less than
the two-stage procedure. There is currently uncertainty
regarding the best treatment option.
There have been no randomised controlled trials com-
paring one- and two-stage revision procedures. However,
several observational studies have assessed re-infection
outcomes following the one-stage or two-stage surgical
revisions and have reported inconsistent results. Wolf
and colleagues conducted a literature review in 2008 and
used a decision analysis to compare the one- and two-
stage revision strategies [11]. In their search of only
MEDLINE and the American and British editions of The
Journal of Bone and Joint Surgery, 11 two-stage (321 pa-
tients) and eight one-stage (576 patients) studies were
included in the review. In pooled analysis, they reported
an increased re-infection rate after one-stage (12.3%)compared to two-stage revision (6.5%) of infected total
hip replacements [11]. There was however a higher mor-
tality rate associated with the two-stage compared to
one-stage. Using a Markov cohort simulation decision
analysis, they reported that the overall balance of risk
and benefit favours the one-stage approach in the treat-
ment of infection after a total hip replacement. Lange
and colleagues in their systematic review and meta-
analysis included a total of 36 published studies (compris-
ing 375 one-stage and 929 two-stage patients), identified
from a search of PUBMED, EMBASE, Cochrane Library
and the WHO International Clinical Trials Registry Plat-
form databases till 2010 [12]. Re-infection rates of 13.1%
and 10.4% were reported for one- and two-stage revision
strategies, respectively. Our group has also recently
assessed re-infection outcomes of one- and two-stage re-
vision of infected hip replacements using published stud-
ies that included populations representative of patients in
routine clinical practice [13]. In a search of EMBASE,
MEDLINE and Cochrane databases, 11 one-stage (1,225
patients) and 28 two-stage (1,188 patients) studies were
included in the review. Pooled random-effects meta-
analysis yielded a lower re-infection rate at 2 years for
one-stage-revision (8.6%) compared to a two-stage revi-
sion (10.2%), although this difference was not significant.
The inconsistent evidence does not conclusively support a
specific revision strategy for prosthetic hip infection. In
addition, there were several features of these aggregate re-
views which limit the validity of the findings. Firstly, none
of the reviews performed a detailed quality assessment of
the included studies. Secondly, the heterogeneous defin-
ition of re-infection outcomes by the studies included did
not allow reliable comparison of the findings. Though our
review attempted to minimise this by assessing only re-
infection outcomes within 2 years of revision surgery, this
approach was not possible in all studies. Thirdly, there
was substantial heterogeneity amongst contributing stud-
ies which could not be adequately explored. Finally, ma-
jority of these reviews did not conduct any subgroup
analysis or assess the possibility of publication bias.
Given these limitations of aggregate published data,
the results of the previous reviews may be misleading
and potentially promote inappropriate recommendations
for a specific strategy for revision of infected hip pros-
theses. To compare the effectiveness of one-stage and
two-stage revision will require robust evidence from a
carefully designed randomised clinical trial. With the
low incidence of prosthetic hip infection, an appropriate
definitive randomised trial with re-infection as the pri-
mary outcome is currently unlikely. In the absence of
such a clinical trial, we propose the Global Infection
Orthopaedic Management (INFORM) collaboration, a
worldwide collaborative systematic review and meta-
analysis of individual participant data (IPD) to address
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will enable a consistent approach to the definition of re-
infection outcomes, more detailed analyses under a
broader range of circumstances, exploration of potential
sources of heterogeneity and produce much more valid
and precise estimates of re-infection outcomes.
Aims and objectives
The main aim of this worldwide collaborative systematic
review and meta-analysis of IPD is to compare the ef-
fectiveness of one- and two-stage surgical revision to
prevent re-infection following prosthetic hip infection.
Specific objectives are as follows:
1. To compare characteristics of patients undergoing
one-stage or two-stage revision surgery following
prosthetic hip infection
2. To assess average time to re-infection following one-
stage or two-stage revision surgery
3. To assess incidence of re-infection (primary
outcome) for one-stage or two-stage revision surgery
4. To compare risk of re-infection for one-stage
compared to two-stage revision surgery following
adjustment for potential confounders
5. To compare risk of re-infection for one-stage
compared to two-stage revision surgery in clinically
relevant subgroups
6. To compare other outcome measures such as
patient reported function, readmission, pain and
death (when data permits).
Methods
We will conduct this systematic review and IPD meta-
analysis using a predefined protocol and in accordance
with methods recommended by the IPD Meta-analysis
Methods Group of the Cochrane Collaboration [14] and
other published guidelines [15]. Results will be reported
in accordance with relevant aspects of PRISMA and
MOOSE guidelines [16,17]. In accordance with the
PRISMA 2015 statement [18,19], in the event of an im-
portant protocol amendment - the date of the amend-
ment, description of the amendment and rationale for
amendment will be provided. A revised protocol will be
generated which will list the specific amendments made
to the previous version. The lead investigator will be re-
sponsible for approving and supervising the documenta-
tion and implementation of the amendments.
Data sources and search strategy
We will update the literature search to identify new
studies published since the completion of our systematic
review [13] which compared the effectiveness of one-
stage and two-stage revision for re-infection outcomes
following prosthetic hip infection. We will systematicallysearch for longitudinal studies (retrospective, prospective
or randomised controlled trials) reporting re-infection
outcomes following one- or two-stage surgical revision
of infected hip prosthesis in MEDLINE, EMBASE, Web
of Science, Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials and the
WHO International Clinical Trials Registry Platform
from March 2011 (date of our last search for the previ-
ous review) to date. The computer-based searches will
combine free and MeSH search terms and combination
of keywords related to hip replacement, infection and re-
vision with focus on one- and two stage revision surger-
ies. There will be no restrictions on language. Reference
lists of retrieved articles will be manually scanned for all
relevant additional studies and review articles. An add-
itional Microsoft Word file shows the search strategy in
more detail [see Additional file 1]. To minimise publica-
tion bias, information on studies in progress (Clinical
Trials.gov) and studies reported in the grey literature
[Systems for Information in Grey Literature (SIGLE) and
Dissertation abstracts] will be sought. See Figure 1 for
preliminary PRISMA flow of studies.
Eligibility criteria
Studies will be included if they involve unselected pa-
tients with prosthetic hip infection (over 18 years of age)
treated exclusively by one-stage or two-stage revision
and had at least been followed up for 2 years for re-
infection outcomes after revision surgery. Studies that
report case series of methods in selected group of pa-
tients (such as subsamples of patients who received revi-
sion in one or two stages or patients with a specific
infection), did not include patients with less than 2 years
of follow-up, and studies with less than ten participants
will be excluded from the review.
Study selection and quality assessment
Two investigators will independently review titles and
abstracts for eligibility. If either reviewer determines that
a study may be eligible based on title or abstract review,
then a full-text article review will be completed. Each
article will be assessed using the inclusion criteria above
and any disagreement regarding eligibility of an article
will be discussed, and agreement reached by consensus
with a third reviewer. All studies in languages other than
English will be translated into English. Methodological
quality will be assessed based on the Methodological
Index for Non-Randomised Studies (MINORS), a vali-
dated instrument which is designed for assessment of
methodological quality of non-randomised studies in
surgery [20]. For non-comparative studies, it uses eight
pre-defined domains namely: a clearly stated aim, inclu-
sion of consecutive patients, prospective collection of
data, endpoints appropriate to the aim of the study,
Figure 1 Draft PRISMA flow diagram.
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period appropriate to the aim of the study, loss to
follow-up less than 5% and prospective calculation of
the study size. For each item, MINORS assigns 0 for not
reported, 1 for reported but inadequate, or 2 for re-
ported and adequate. The global ideal score is 16.
Establishment of the Global INFORM collaboration
Investigators of eligible studies will be invited to join the
collaboration by providing us with individual level data.
We will identify contact information from the published
studies or an online search. Each principal investigator
will be contacted and provided with the protocol and a
cover letter. Based on our recent published review [13],
we have identified key studies that may potentially con-
tribute data to this collaboration. We are also in the
process of updating our previous review as several im-
portant studies have been published since its publication.A number of authors of studies have expressed initial
interest to collaborate in this effort [21-28] (Table 1).
Data collection
Investigators will be provided with a list of relevant
study variables that could be used in the analyses
(Table 2), and data dictionaries will be requested. We
will accept data in all formats but preferably in STATA,
SPSS or Microsoft Excel. Individual level data collected
will be cleaned, coded and entered into a single STATA
database (Stata Corp, College Station, TX, USA).
Statistical analysis
Re-infection within 2 years of hip revision surgery will
be used as the primary outcome. Secondary outcomes
will include further treatments (such as re-revision sur-
gery), pain, functional outcomes and death. No formal
sample size requirements are necessary for the meta-
Table 1 Characteristics of studies with provisional support to share individual level data
Lead author, publication date
(reference number)
Location Year of study Mean/median
age (years)
% male Follow-up
mean/median
(months)
Type of
re-implantation
Use of
spacer
Number of
re-infections
Number of
participants
Type of
revision
Elson et al. 1993 [21] UK NS NS NS NS NS NA 33 235 One-stage
Whittaker et al. 2009 [22] UK 1998 to 2003 69.0 49.0 49.0 Both Spacer 6 43 Two-stage
Cabrita et al. 2007 [23] Brazil 1996 to 2003 54.6 58.0 48.0 NS Spacer 4 38 Two-stage
Ritter et al. 2010 [25] USA 1969 to 2004 66.2 52.0 82.8 NS NS 5 17 Two-stage
De Man et al. 2011 [24] Switzerland 1985 to 2004 70.0 57.0 45.6 NS NS 1 55 One-stage
Neumann et al. 2012 [26] Austria 2000 to 2008 25 to 84a 56.8 67.0 Cementless Spacer 1 44 Two-stage
Schwarzkopf et al. 2014 [27] USA 2001 to 2011 62.3 46.9 32.4 Cemented Spacer 3 62 Two-stage
Zeller et al. 2014 [28] France 2002 to 2010 71.0 58.0 41.6 Cementless NA 6 157 One-stage
NA, not applicable; NS, not stated; Both, some participants had cemented re-implantation and others cementless.
aAge range.
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Table 2 Study variables to be requested for individual participant data meta-analysis
Broad classification Variables
Socio-demographic characteristics Country in which study was carried out, age, sex, body mass index (weight and height) and
smoking status
Past medical/surgical history Previous hip surgery, other joint surgery and comorbidities (for example, history of diabetes),
Charnley classification, Charlson index, ASA grade
Infection characteristics before revision surgery Duration between index implantation and occurrence/diagnosis of infection, duration between
diagnosis of infection and revision surgery
Baseline laboratory data for infection CRP, ESR, leucocytes, causative organism, neutrophil count, white cell count, synovial fluid white
cell count, IL-6
Characteristics of surgical revision Date of revision, type of re-implantation, type of fixation (cemented or uncemented), use of spacer,
type of spacer (static or articulating), use of antibiotics in cement or spacer, time interval between
stages for two-stage procedure, diagnosis of re-infection, date of diagnosis of re-infection or date of
last follow-up for participants without re-infection, time to re-infection or last follow-up (days or
years), antibiotics used and duration of antibiotics
Intervention One- or two-stage revision
ASA, American Society of Anaesthesiologists; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IL-6, interleukin-6.
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the one-stage to the two-stage (reference category) pro-
cedure. IPD analyses will be based on Cox proportional
hazard (PH) models estimated for each study separately.
All PH models will be stratified by sex and adjusted for
age, body mass index, comorbidities and other potential
confounders. Study-specific log hazard ratios (HRs) will
be combined using random-effects meta-analysis. Between-
study heterogeneity will be quantified by the I2 statistic.
Supplementary analyses will combine log HRs using fixed-
effects meta-analysis. Given the distortions (for example,
non-convergence of statistical models) that can appear in
analyses involving small strata (such as studies contribut-
ing less than ten outcomes to a specific analysis) when
using two-stage PH models, a single-stage PH model
which maintains clustering of the data will also be consid-
ered. In subsidiary analyses, a propensity score approach
will also be used to compare re-infection outcomes be-
tween the two types of revisions. Comparison of the one-
to two-stage approach for re-infection incidence may vary
under different circumstances. There is therefore no rea-
son to expect a priori that the results will be similar for
example in patients with/without a history of diabetes or
in regions that have different underlying infection pat-
terns. It is therefore important to investigate the compari-
sons according to different level characteristics. Therefore,
primary analyses will be repeated to calculate HRs for re-
infection according to different individual and study level
characteristics such as sex, age groups, body mass index,
comorbidities, major geographical regions (that is, Europe/
North America/Australia/NZ, South Asia and East Asia)
and study quality (low versus high quality studies).
Sensitivity analysis will include determining HRs for re-
infection on exclusion of low-quality studies. The po-
tential impact of publication bias and unavailable data
will be explored in accordance with methods proposed
by Ahmed and colleagues [29]. Funnel plots will also beconstructed to examine the likelihood of publication
bias. All analyses will be conducted using Stata version
13 (Stata Corp, College Station, TX, USA).
Ethical issues
We will not seek ethical approval for this systematic and
IPD meta-analysis, because we will be collecting and
synthesising the same data from previously published
studies in which informed consent and ethical approval
has already been obtained by the study investigators
(which will be confirmed in the published study and in
writing). Secondly, our systematic review and IPD meta-
analysis will be addressing similar questions to the re-
search question for which the data were collected.
Thirdly, we will request investigators to submit anon-
ymised datasets. Finally, our Research Ethics Committee
has confirmed that ethical approval is not required for
the present study, given the above reasons. Our research
is supported by an established patient forum [30], and
we will seek advice on issues relating to review conduct
and dissemination of results.
Proposed collaborative publication arrangements
It is proposed that the following collaborative arrange-
ments should be used in this effort: 1) scientific papers
will be published in the name of a collaborative group
(for example, ‘Global Infection Orthopaedic Manage-
ment Collaboration’), 2) the members of a writing com-
mittee are to be listed at the end of the paper with a
small number of representatives (for example, three
from each of the contributing studies sharing data), 3)
the sequence of names in the writing committee is to be
arranged to help demonstrate the collaborative nature of
this effort (for example, each study will be able to in-
clude one ‘starred’ joint first author and one ‘starred’
joint final author), 4) in addition to the researchers listed
in the writing committee and the analytical subcommittee,
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itional scientists who have made contributions to this ef-
fort (for example, under the heading ‘Investigators’, it may
be possible to list principal investigators from each of the
component studies, subject to the approval of the paper’s
target journal, which has not yet been determined). The
Cochrane IPD meta-analysis method group recommends
a collaborators’ meeting for preliminary presentation of
meta-analyses [31]. We anticipate that this will take the
form of a teleconference but will explore the feasibility of
holding a workshop locally or at an appropriate inter-
national conference.
Discussion
The present analysis will differ from the previous re-
views in the following main ways: (i) access to individual
level data should enable a consistent approach to the
definition of the primary outcome (2-year incidence of
re-infection), a common approach across studies to stat-
istical analyses and a consistent approach to adjustment
for potential confounders, a greater ability to explore
and identify sources of between-study heterogeneity, com-
parison of the one- to two-stage revision for re-infection
incidence under different level characteristics and ability
to assess secondary outcomes such as patient-reported
function, pain and death; (ii) statistical power - as the
present analysis will involve several-fold more partici-
pants, it should be substantially more powerful and pre-
cise than previous individual studies and reviews; (iii)
generalisability - as it is anticipated to include studies with
populations representative of patients in routine clinical
practice, the results from the present meta-analysis should
be more generalisable. Moreover, inclusion in the pro-
posed analysis of key prospective studies worldwide
should help avoid biases due to selective inclusion of stud-
ies and enhance the generalisability of the study results.
Registration
The protocol for the systematic review and IPD meta-
analysis has been registered with PROSPERO, the
international prospective register of systematic reviews,
(PROSPERO 2015: CRD42015016664). Available from
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?
ID=CRD42015016664.
Additional file
Additional file 1: Search strategy for MEDLINE.
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